The detection of radioiodine (I-131)-negative
metastases of differentiated
thyroid carcinoma (DTC) has been hitherto successfully tried by the well-known synthetic
somatostatin analogue indium-111-labeled
DTPA-
octreotide (In-111 pentetreotide). The objective of this study was to evaluate the usefulness of scintiscan with the newer synthetic
somatostatin analogue
Tc-99m depreotide, in the restaging of
papillary thyroid carcinoma (PTC) with detectable serum
thyroglobulin (Tg) levels and negative I-131 whole-body scan (WBS). Whole-body planar and cervico-thoracic tomographic scintigraphy (single-photon emission tomography-SPET) with
Tc-99m depreotide was performed in a 68-year-old male patient suffering from PTC stage III, with a mild increase in serum Tg levels coupled with a recent negative I-131 WBS. The findings were compared with those of neck ultrasonography (US) and computerized tomography (CT). Nodal
neck dissection and histopathology provided the definitive diagnosis.
Tc-99m depreotide scanning revealed foci of cervical
lymph node metastases, which did not accumulate I-131. The findings were in accordance with neck US and CT. Histopathology established the diagnosis of metastatic cervical lymph node PTC. Lymph node immunoreactivity was positive for the
somatostatin receptor subtypes 2, 5 and 3. Scintigraphy with
Tc-99m depreotide could prove a useful adjunct to the armamentarium for the follow-up of PTC, especially in the setting of detectable serum Tg and negative I-131 WBS.